Combination therapyFDA-approvedFirst-line

Tafinlar + Mekinist

Generic name: dabrafenib + trametinib

How it works

Combination of dabrafenib, which blocks the BRAF V600E mutation, and trametinib, which blocks the MEK protein, to inhibit cell growth and division.

Cancer types

Melanoma— BRAF V600E-positive

Efficacy

Studies show that around 50% of patients achieve an objective response, with median progression-free survival of approximately 9 months.

Side effects

Moderate

Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.